PhaseBio PlansFfor Near-Term Sale Using Structured Process Through Chapter 11 Pf US Bankruptcy Code
Author: Bill Haddad | October 24, 2022 08:05am
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. As part of the case, PhaseBio also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures, if approved by the court, would require interested parties to submit binding offers to acquire PhaseBio's bentracimab program assets, which would be purchased free and clear of liens and interests.
Posted In: PHAS